Drug profile · INN
tagraxofusp-erzs
ELZONRIS
tagraxofusp-erzs (ELZONRIS) is a elongation factor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — tagraxofusp-erzs
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tagraxofusp-erzs (ELZONRIS) is a elongation factor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Elongation factor 2 inhibitor
Primary target: Elongation factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is tagraxofusp-erzs?
tagraxofusp-erzs (ELZONRIS) is a elongation factor 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tagraxofusp-erzs?
ELZONRIS is a marketed brand name for tagraxofusp-erzs. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tagraxofusp-erzs?
tagraxofusp-erzs has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.